Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals Announces Positive Interim Data from Phase 1 Clinical Trial of IMO-2125 in Chronic Hepatitis C Patients
Published in Hepatitis Weekly, January 4th, 2010
In this four-week trial, IMO-2125 was well tolerated and induced dose-dependent increases in endogenous interferon-alpha and other cytokines. IMO-2125 also demonstrated a treatment-related decrease in viral load at escalating dose levels. All patients enrolled in the trial are null responders, which is defined as patients who have...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2010-01-04)
More Articles from Hepatitis Weekly
- Diabetes
Studies in the area of diabetes reported from University of South Dakota - Hepatitis C Virus
Findings from University of Birmingham broaden understanding of hepatitis C virus - Hepatitis C Virus
Research from University of Kiel in the area of hepatitis C virus described - Hepatitis C Virus
Scientists at Boston University, Medical Department target hepatitis C virus - HIV/AIDS
Research results from N. Merchante and colleagues update understanding of HIV/AIDS - Transfusion Medicine
New findings from INSERM in the area of transfusion medicine described - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
